Assessment of new technologies

	Tweet

The dominant framework for medical technology regulation and evaluation has historically been based on therapeutics, whereas early detection relies on screening and diagnostic methods.  The evaluation of therapeutic and detection technologies, however, may be intrinsically different. The stages of development for drugs are more standardized, and therapeutic interventions generate direct outcomes that can be observed in patients. In contrast, most patient-level effects of screening and diagnostic tests are mediated by subsequent therapeutic decisions.

Screening and diagnostic tests also generate information that is subject to interpretation.  Furthermore, this information is only one of the inputs into the decision-making process. Hence, the evaluation of detection technologies is fundamentally an assessment of the value of information. The development process for devices also tends to be iterative, and thus, assessment at early stages of development may not recognize the full potential of a new medical device. That is, most technologies that ultimately achieve widespread use go through successive stages of development, variation, and appraisal of the actual experience in the market.

With the exception of mammography, new breast cancer detection technologies have been evaluated by diagnostic studies that primarily measure sensitivity (the proportion of people with the disease who test positive) and specificity (the proportion of people without the disease who test negative). Even if the technologies ultimately are intended to be used for screening, they are generally not evaluated through screening studies that measure health outcomes. 

Adoption of new detection technologies for screening purposes before assessment of their effects on clinical outcome has been common and quite problematic for technologies used to screen for other diseases because data on detection accuracy are not adequate to assess the potential value of new technologies for screening.  The ideal end points for assessment of screening technologies are reductions in disease-specific mortality or morbidity, or both, but the clinical trials needed to measure those end points are quite large, lengthy, and costly.

Surrogate end points for morbidity and mortality are difficult to define because the net effect of new detection technologies could be either positive (more accurate detection, leading to lower breast cancer mortality) or negative (capable of identifying more lesions but not changing disease-specific mortality and thus leading to greater morbidity and higher screening costs).

###

Sharyl J. Nass, I. Craig Henderson, and Joyce C. Lashof
Committee on Technologies for the Early Detection of Breast Cancer

National Cancer Policy Board INSTITUTE OF MEDICINE and Division of Earth and Life Studies
NATIONAL RESEARCH COUNCIL

RELATED STORIES:
Conclusion - Biology of High Risk Benign Breast Lesions   Invasion and Proteases   Tamoxifen and the Risk of Contralateral Breast Cancer: Role as a Chemopreventive Agent   Surgery for Invasive Breast Cancer   Chemotherapy - Breast Cancer Palliative Treatment   Benign Breast Diseases   Role of High-Dose Chemotherapy for High-Risk Breast Cancer   Hereditary Breast Cancer Summary   Screening for Breast Cancer - Conclusion   Follow-Up Care   Menopausal Health After Breast Cancer   Nodularity   Breast Cancer Differential Diagnosis   Prevention Strategies for Women with BRCA1 or BRCA2 Mutations   Epithelial Hyperplasia   Surgery for Locally Advanced Breast Cancer   Breast Abscess   Mammography Trials and Meta-Analyses   Technique of Mastectomy   Breast Cancer in Black Women   Surveillance Options for Individuals with BRCA1 or BRCA2 Mutations   Uterine or Ovarian Enlargement in patients with breast cancer

Comments

[ + Post Your Own ]

Now you're in the public comment zone. What follows is not Armenian Medical Network's stuff; it comes from other people and we don't vouch for it. A reminder: By using this Web site you agree to accept our Terms of Service. Click here to read the Rules of Engagement.

There are no comments for this entry yet. [ + Comment here + ]